Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03072160|
Recruitment Status : Completed
First Posted : March 7, 2017
Last Update Posted : June 9, 2020
Medullary thyroid cancer (MTC) is a tumor of the thyroid gland. Surgery is the only current treatment to cure it. The drug pembrolizumab (MK-3475) is a new type of cancer therapy. It works by allowing the immune system to detect and kill tumor cells.
To test how pembrolizumab affects people with MTC and if it can offer them clinical benefit.
People ages 18 and older with MTC
Patients who have recurrent or metastatic MTC, for whom surgery is not a curative option
Patients with some imaging evidence of MTC
Patients with minimal symptoms related to MTC
Participants will be screened with:
- Medical history
- Physical exam
- Blood, urine, and heart tests
- CT scan or MRI: They lie in a machine that takes pictures of the body.
- Bone scan
Participants will be put in a group based on their treatment history:
- Group 1 if they have had an immune stimulating cancer vaccine
- Group 2 if they have had no vaccine
Participants will receive the study drug as a 30-minute IV infusion every 3 weeks. Treatment will continue for up to 2 years as long as they tolerate it and their disease does not get worse.
Participants will have physical exams and blood tests on the day of each infusion. They will have CT and bone scans every 3 months.
Participants may save biopsies before treatment and after starting treatment.
Participants will have a final visit 3-4 weeks after stopping treatment. This will include a physical exam and blood and heart tests.
After this study, participants will can join a long-term follow-up study.
|Condition or disease||Intervention/treatment||Phase|
|Medullary Thyroid Cancer (MTC)||Drug: Pembrolizumab||Phase 2|
- Anti PD1/PDL1 therapies have had clinical success in a minority of unselected patients across multiple tumor types
- While many questions remain about optimal PD1/PDL1 staining techniques to pre-select responders, less focus is being place on how to optimize responses in a broader cohort of patients
- Emerging preclinical and clinical data supports the hypothesis that a strong immunologic response in the tumor microenvironment induces PDL1 expression on the tumor and is associated with better clinical response to anti-PD1/PDL1 therapies
- Therapeutic cancer vaccines are one strategy to induce an immunologic response to the tumor, thereby enhancing PDL1 expression and optimizing clinical responses across all patients
- Limited clinical data exists about the potential benefit of sequential therapy with a therapeutic cancer vaccine followed by PD1/PDL1 inhibition
- This study will explore the role of PD1 inhibition in medullary thyroid cancer and evaluate the potential differences based on previous vaccine therapy
-The primary objective of this trial is to determine whether administering a PD1 inhibitor to patients with medullary thyroid cancer will permit a modest fraction to be able to experience a 50% or greater decline in calcitonin levels or experience a partial/complete response on imaging
- Patients greater than or equal to 18 years of age with evidence of metastatic medullary thyroid cancer including disease that is evaluable on bone, CT scan or MRI
- Must have elevated calcitonin levels greater than 40 pg/mL
- Patients with minimal or no disease related-symptoms (minimal symptoms will include those that do not affect activities of daily living or pain that does not require regularly schedule narcotics)
- ECOG 0-1
- Should have no autoimmune diseases; no evidence of being immunocompromised; no serious inter-current medical illness
- No brain metastasis, history of seizures, encephalitis, or multiple sclerosis
- This is a phase II, open label, single center clinical trial where all patients receive the anti-PD1/PDL1 therapy pembrolizumab
- Patients will enroll in one of two cohorts: patients with previous vaccine therapy or patients without previous vaccine therapy
- All patients will be TKI -na(SqrRoot) ve, with minimal symptoms (consistent with the eligibility for our current study)
- Based on our calcitonin findings with our current study of 30 patients, we have determined that a confirmed calcitonin decline of 50% would be a rare finding, providing compelling preliminary evidence of clinical activity
- A total of 30 patients will be enrolled in the proposed study (15 patients in each cohort). Given that we already have 30 patients on a study with vaccine, we would only need to identify and recruit 15 na(SqrRoot) ve patients for the vaccine-naive cohort. This accrual could be done in 18 months based on our current accrual rates
- Based on these metrics, we could have >6 months of calcitonin data in 30 patients within 2 years from trial initiation
- Additional immune correlative capitalizing on the extensive immune monitoring experience of the LTIB will allow for assessments of antigen specific T-cells and 123 immune subsets. These findings could provide the basis for biomarker development when taken together with biochemical and clinical responses seen in this study
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||17 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer|
|Actual Study Start Date :||June 16, 2017|
|Actual Primary Completion Date :||November 22, 2019|
|Actual Study Completion Date :||November 22, 2019|
Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks for two years.
Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
- Determine whether a PD1 inhibitor will permit a decline in calcitoninlevels or response on imaging in patients with medullary thyroidcancer [ Time Frame: One Year ]Determine whether administering a PD1 inhibitor to patients withmedullary thyroid cancer will permit a modest fraction to be able toexperience a 50% or greater decline in calcitonin levels or experiencepartial/complete response on imaging
- Determine the impact of previous therapeutic cancer vaccine on response rates [ Time Frame: 3 weeks for up to 2 years while on treatment then 2 weeks after last treatment ]The response rate between those patients that previously received a vaccine vs. those who did not will be determined and reported along with a 95% confidence interval.
- Evaluate immune responses in each cohort [ Time Frame: every 3 months for up to 2 years while on treatment and 3 weeks post treatment ]Subsets of immune cells will be followed in response to treatment.
- Changes in CEA and Calcitonin kinetics [ Time Frame: every 3 weeks for up to 2 years while on treatment and 3 weeks post treatment ]Changes in CEA and calcitonin will be followed in response to treatment.
- Progression-free survival and overall survival [ Time Frame: 3 weeks for up to 2 years while on treatment then 2 weeks after last treatment ]The response rate will be determined and reported along with a 95% confidence interval.
- Safety of anti-PD1/PDL1 therapy pembrolizumab [ Time Frame: 3 weeks for up to 2 years while on treatment then 2 weeks after last treatment ]type, number and frequency of adverse events
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03072160
|United States, Maryland|
|National Institutes of Health Clinical Center|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Ravi A Madan, M.D.||National Cancer Institute (NCI)|